Werewolf Therapeutics, Inc.

How big is Werewolf Therapeutics, Inc.?

As of Jun 18, Werewolf Therapeutics, Inc. has a market capitalization of 54.30 million, with net sales of 1.14 million and a net profit of -72.41 million over the latest four quarters. Shareholder's funds are at 73.39 million, and total assets amount to 129.50 million.

As of Jun 18, Werewolf Therapeutics, Inc. has a market capitalization of 54.30 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 1.14 million, while the sum of Net Profit for the same period is -72.41 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 73.39 million and Total Assets at 129.50 million.

What does Werewolf Therapeutics, Inc. do?

Werewolf Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $18 million and a market cap of $54.30 million. Key metrics include a negative P/E ratio, no dividend yield, and a return on equity of -127.93%.

Overview: <BR>Werewolf Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -18 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 54.30 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.12 <BR>Return on Equity: -127.93% <BR>Price to Book: 0.95<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Should I buy, sell or hold Werewolf Therapeutics, Inc.?

Is Werewolf Therapeutics, Inc. overvalued or undervalued?

As of August 14, 2025, Werewolf Therapeutics, Inc. is considered overvalued with a valuation grade of "does not qualify," highlighted by a Price to Book Value of 1.11, a low EV to Capital Employed of 0.05, and a negative ROE of -127.93%, while significantly underperforming its peers and the S&P 500.

As of 14 August 2025, the valuation grade for Werewolf Therapeutics, Inc. has moved from risky to does not qualify, indicating a deterioration in its investment appeal. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 1.11 and an EV to Capital Employed of just 0.05, which suggest that the market may be pricing in more value than the company can deliver. Additionally, the ROCE stands at an impressive 1104.53%, but this is overshadowed by a negative ROE of -127.93%, highlighting significant financial challenges.<BR><BR>In comparison to its peers, Chimerix, Inc. has a P/E ratio of -8.6897, while CytomX Therapeutics, Inc. stands out as very attractive with a P/E of 7.4924. This suggests that Werewolf Therapeutics is not only lagging behind its competitors but also struggling to establish a solid valuation framework. Over the past year, the stock has returned -34.68%, significantly underperforming the S&P 500's 17.14%, reinforcing the notion that the stock is overvalued in the current market context.

Is Werewolf Therapeutics, Inc. technically bullish or bearish?

As of September 11, 2025, Werewolf Therapeutics, Inc. shows a mildly bullish trend with positive signals from the weekly MACD and moving averages, despite mixed indicators in other metrics and a year-to-date return of -2.03% compared to the S&P 500's 12.22%.

As of 11 September 2025, the technical trend for Werewolf Therapeutics, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. However, the monthly KST is bearish, and the Bollinger Bands show a mildly bearish signal on that same timeframe. The Dow Theory indicates a mildly bullish trend on the weekly chart, while the OBV is mildly bullish on the weekly but mildly bearish on the monthly.<BR><BR>In terms of performance, the stock has returned 9.02% over the past month, significantly outperforming the S&P 500's 2.33% return in the same period. However, the year-to-date return is -2.03%, lagging behind the S&P 500's 12.22%. Overall, the current technical stance is mildly bullish, driven by positive signals from the MACD and moving averages, despite some mixed indicators in other metrics.